Kinneret

Global Biologics Market Research Report 2021-2026 - Rising Demand for Biologics in Treatment of Chronic Diseases - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 13, 2021
Health, Biotechnology, Government, Technology, Diabetes, Rheumatoid arthritis, Adalimumab, Enzyme, Biopharmaceutical, CAGR, Growth, Hormone, Population, Benchmarking, Kinneret, CMO, Infection, Neutralizing antibody, Oligonucleotide, Vaccine, Disease, Outsourcing, Conditional sentence, Patient, Psoriasis, Health, Recombinant, Research, Cytokine, COVID-19, Pharmaceutical industry, Fine chemical

The "Global Biologics Market Research Report: Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biologics Market Research Report: Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, regulatory approval from the governments in different countries is also contributing to the growth of the Biologics market.
  • What are the overall market statistics or estimates (Market Overview, Market Size - by Value, Forecast Numbers, Market Segmentation, and Market Shares) of the Global Biologics Market?
  • What are the key results derived from the market surveys conducted during the Global Biologics Market study?

FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)

Retrieved on: 
Tuesday, December 22, 2020
Medical specialties, Clinical medicine, Medicine, Rheumatology, Immunosuppressants, Anakinra, Cytokines, Kinneret, Interleukin 1 receptor antagonist, Interleukins, Arthritis, Interleukin-1 family

The safety and efficacy of KINERET were evaluated in a long-term natural history study, including nine patients with DIRA (ages 1 month to 9 years at start of KINERET treatment) treated with KINERET for up to 10 years.

Key Points: 
  • The safety and efficacy of KINERET were evaluated in a long-term natural history study, including nine patients with DIRA (ages 1 month to 9 years at start of KINERET treatment) treated with KINERET for up to 10 years.
  • At the last visit during the first KINERET treatment period, the dose ranged from 2.2 and 6.1 mg/kg/day.
  • KINERET(anakinra) is a prescription medicine called an interleukin-1 receptor antagonist (IL-1Ra) used to:
    KINERET is not for children with Juvenile Rheumatoid Arthritis.
  • A complete list of any of the ingredients in KINERET can be found at the end of the patient leaflet.

Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority

Retrieved on: 
Friday, December 18, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Corporate finance, Private equity, Entrepreneurship, Venture capital, Kinneret, Economy, FutuRx, Atomwise

Recently, Leaps by Bayer has joined as a new investor alongside FutuRxs founding investors to incept and incubate early-stage biotech companies.

Key Points: 
  • Recently, Leaps by Bayer has joined as a new investor alongside FutuRxs founding investors to incept and incubate early-stage biotech companies.
  • A2i Therapeutics near-term research activities will be funded by capital contributions from the Israeli Innovation Authority, the FutuRx investors, and in-kind resources and support provided by Atomwise.
  • FutuRx is excited to launch a new bio convergence company jointly with a world leader in AI-based drug discovery, said Kinneret Savitzky, PhD, Chief Executive Officer of FutuRx.
  • Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.